MJ

Marcellus Johannes Velterop

Director Director DIN 08242333
DIN 08242333 First appointment Oct 2018 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Oct 2018
Shareholding value β€’β€’β€’β€’ Premium profile

About Marcellus Johannes Velterop

Data last updated:

Marcellus Johannes Velterop was a Director at Jubilant Biosys Limited (2018–2021) and Director at Jubilant Chemsys Limited (from 2018). The companies operate in Pharma.

DIN 08242333
Primary Designation Director
Industry Pharma
First Appointment 03 Oct 2018
Oldest Company Age 22 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Jubilant Biosys Limited U24110UP1998PLC029591
Director03 Oct 20181998₹563 Cr (FY 2023)Active
Jubilant Chemsys Limited U24232UP2004PLC029009
Director03 Oct 20182004₹126 Cr (FY 2019)Amalgamated

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Jubilant Chemsys Limited
Jubilant Biosys Limited
Premium access

Shareholding and investment profile for Marcellus Johannes Velterop

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Marcellus Johannes Velterop

Marcellus Johannes Velterop was first appointed on 03 Oct 2018 as Director at Jubilant Biosys Limited.

Marcellus Johannes Velterop held 2 earlier board appointments: Jubilant Biosys Limited (Director, 03 Oct 2018 to 15 Jul 2021); Jubilant Chemsys Limited (Director, from 03 Oct 2018).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available